Sign In
Buy VRTX
$428.34
+3.25 (+0.765%)
At Close: Jun 03, 2026
Why Vertex Pharmaceuticals' Shares Rose 2.8% in September
09:51am, Wednesday, 05'th Oct 2022
The company has a potential blockbuster drug that was granted rolling review status by the FDA.
3 Healthcare Stocks That Could Make You Richer
06:30am, Wednesday, 05'th Oct 2022
It's all about much-needed products.
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
02:23pm, Tuesday, 04'th Oct 2022 The Motley Fool
These biotech stocks are finding game-changing therapies, and their shares are up as a result.
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
01:00pm, Tuesday, 04'th Oct 2022 Zacks Investment Research
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
1 Growth Stock That'll Beat Amazon and 1 That Probably Won't (for Now)
10:40am, Tuesday, 04'th Oct 2022 The Motley Fool
The two companies are collaborators, but they aren't equally likely to be a better purchase than Amazon.
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
10:32am, Tuesday, 04'th Oct 2022
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
1 Growth Stock That'll Beat Amazon and 1 That Probably Won't (for Now)
06:40am, Tuesday, 04'th Oct 2022
The two companies are collaborators, but they aren't equally likely to be a better purchase than Amazon.
Vertex Pharmaceuticals: A Buy For Growth Potential
04:26am, Tuesday, 04'th Oct 2022 Seeking Alpha
Vertex’s cystic fibrosis franchise is the main source of value at present. Learn more about VRTX stock and my recommendation.
Vertex Pharmaceuticals: A Buy For Growth Potential
12:26am, Tuesday, 04'th Oct 2022
Vertex's cystic fibrosis franchise is the main source of value at present. Q2 revenue was up 22% from the year-earlier.
Spiros Segalas Snatches Up Vertex Pharmaceuticals, Sells Snap
05:15pm, Monday, 03'rd Oct 2022
Spiros Segalas (Trades, Portfolio), manager of the Harbor Capital Appreciation Fund, disclosed his 13F portfolio for the third quarter of 2022 last week.
Vertex Among 9 Stocks To Watch In Struggling Market
03:19pm, Monday, 03'rd Oct 2022
As the market indexes work through a downturn, Vertex is among nine stocks to watch showing relative strength. The post Vertex Among 9 Stocks To Watch In Struggling Market appeared first on Investor's
bluebird's (BLUE) Gene Therapy Approvals to Drive the Top Line
01:16pm, Monday, 03'rd Oct 2022 Zacks Investment Research
bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, are expected to drive the top line.
3 Growth Stocks Poised to Skyrocket
02:37pm, Saturday, 01'st Oct 2022 The Motley Fool
Two of these three stocks are already soaring this year.
3 Growth Stocks Poised to Skyrocket
10:37am, Saturday, 01'st Oct 2022
Two of these three stocks are already soaring this year.
Got $1,000? 2 Safe Stocks to Buy This Month
01:45pm, Friday, 30'th Sep 2022 The Motley Fool
These stocks can lend growth and peace of mind as you add to your portfolio.
